The United States of America As Represented by the Department of Health

The United States of America

Government of the United States

Immunodiagnostics, Inc.

Thomas M Buchanan

Kirk C Chen

Duane A Olsen

William Pearce

Carl Formoso

Highly immunoreactive regions of gp41 of HIV-1, gp32 of HIV-2 and p24 of HIV-1 were identified using synthetic peptides. Superior immunoassay performance is obtained with these peptides linked to carrier proteins as compared to use of the free peptides. Additional natural and unnatural variants of these reactive regions to define a set of peptides that, as cysteine-linked peptide-protein conjugates, provide optimal immunoassay performance including high immunoreactivity with HIV antibody positive samples, low reactivity with negative samples, high discrimination between positives and negatives, and high specificity. These peptide conjugates further permit simultaneous detection of HIV-1 and HIV-2 antibodies, and make possible rapid and simple test formats that require no instrumentation for detection of these antibodies.

Synthetic HIV-like peptides their compositions and uses

A vaccine affording protection against attachment of Neisseria gonorrhoeae (N.g.) to human cells, and consequent infection, is prepared from a fragment of pili protein isolated from gonococci. This fragment contains the shared antigens between pili from different N.g., in an exposed form.

Neisseria gonorrhoeae vaccine

A vaccine affording protection against infection by Neisseria gonorrhoeae (N.g.) microorganisms is prepared from principal outer protein material isolated from gonococci.

Growing community of inventors

Seattle, WA, United States of America

Thomas M Buchanan